“I’m back to who I am.”
That’s what Rosie Craven had to say of her involvement in HammondCare’s trial of a drug for people living with Alzheimer’s.
Craven has said she’s “back to her happy, easy going self” after joining the trial of Anavex 2-73 in Melbourne.
Principal investigator Professor Stephen Macfarlane, head of HammondCare clinical services, said that before coming on the Phase III trial of the drug, Craven had stopping engaging in activities she previously enjoyed.
“Rosie had enjoyed watching movies and reading but as Alzheimer’s advanced she gave up reading and found it hard to engage with movies, often falling asleep,” Macfarlane said. “Now after being on the trial, Rosie is reading again and loves watching movies and discussing them afterwards.”
The trial also helped Craven more confidently take walks, use her phone and write greetings on cards.
Fellow trial participant Sandra Rozanic also reported finding it easier to engage in hobbies. “I’m feeling a lot better, God yes,” said Sandra.
HammondCare said an earlier Phase II trial saw most participants experience no decline in their cognitive capacity and others improve their mini mental state exam.
So what does Anavex 2-73 do?
Macfarlane said: “We’re still not sure what causes Alzheimer’s disease, but the prevailing theory is the brain is damaged by a build-up of toxic proteins. There have been many failed trials attempting to remove or prevent these proteins.
“The theory behind Anavex 2-73 is that it targets a receptor that, when activated, leads to the removal of these abnormal proteins from brain cells.”
HammondCare has now begun recruiting people aged between 60 and 85 with early stage Alzheimer’s in Sydney.
People in NSW and Victoria interested in learning more can contact the team via email at [email protected] or phone (02) 8437 7355.Do you have an idea for a story?
Email [email protected]